HC Wainwright Has Negative Forecast for ATNM FY2026 Earnings

Actinium Pharmaceuticals, Inc. (NYSE:ATNM) – Investment analysts at HC Wainwright dropped their FY2026 earnings per share (EPS) estimates for Actinium Pharmaceuticals in a research report issued to clients and investors on Tuesday, March 31st. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings per share of ($1.09) for the year, down from their prior estimate of ($0.75). The consensus estimate for Actinium Pharmaceuticals’ current full-year earnings is ($1.41) per share. HC Wainwright also issued estimates for Actinium Pharmaceuticals’ FY2027 earnings at ($0.80) EPS and FY2028 earnings at ($0.86) EPS.

Separately, Stephens reaffirmed an “overweight” rating and issued a $5.00 price objective on shares of Actinium Pharmaceuticals in a research note on Tuesday. Two analysts have rated the stock with a Buy rating, According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $4.50.

Actinium Pharmaceuticals Price Performance

Shares of NYSE:ATNM opened at $0.99 on Thursday. The business has a 50-day moving average of $1.14 and a two-hundred day moving average of $1.35. The firm has a market capitalization of $30.88 million, a PE ratio of -0.71 and a beta of -0.31. Actinium Pharmaceuticals has a 12 month low of $0.95 and a 12 month high of $1.95.

Hedge Funds Weigh In On Actinium Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the business. Mayport LLC acquired a new position in shares of Actinium Pharmaceuticals during the 3rd quarter valued at $35,000. AM Investment Strategies LLC acquired a new stake in Actinium Pharmaceuticals in the 4th quarter valued at $40,000. Qube Research & Technologies Ltd acquired a new stake in Actinium Pharmaceuticals in the 2nd quarter valued at $70,000. Bailard Inc. purchased a new position in Actinium Pharmaceuticals in the fourth quarter valued at about $79,000. Finally, Squarepoint Ops LLC purchased a new position in Actinium Pharmaceuticals in the fourth quarter valued at about $89,000. Hedge funds and other institutional investors own 27.50% of the company’s stock.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on the development of targeted radiopharmaceutical therapies for patients with hematologic malignancies. The company’s proprietary technology platform combines monoclonal antibodies with radioisotopes to deliver highly potent, cell‐killing radiation directly to cancer cells while sparing healthy tissues. Actinium’s lead product candidate, Iomab‐B, is being evaluated as a conditioning regimen for older patients with acute myeloid leukemia (AML) who are ineligible for standard bone marrow transplants.

In addition to Iomab‐B, Actinium’s pipeline includes Actimab‐A, an anti‐CD33 antibody labeled with the radioisotope bismuth‐213 for the treatment of relapsed or refractory AML.